Skip to main content

Table 1 Characteristics of the included studies

From: Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

Included trials

Location (s);

Study design

Eligibility criteria

Gender (male/female);

mean age (years)

Migraine attacks per month

Drug doses

Primary efficacy outcomes at 2 h

Most frequent TEAEs

Control

Trial

Control

Trial

Ferrari MD et al., 2010 [16]

Multinational; RCT

IHS 1.1 & 1.2.1

4/38; 40.3

13/75; 38.4

3.3

3.5

2.5–45 mg

Pain freedom, sustained pain free, other efficacy outcomes such as nausea, photophobia, phonophobia.

Dizziness, paresthesia, fatigue, sensation of heaviness, and feeling of relaxation

Färkkilä M et al., 2012 [17]

Multinational; RCT

IHS 1.1 & 2.1

11/75; 40.5 ± 10.3

38/267; 40.2 ± 11.0

3.1 ± 1.6

3.3 ± 1.7

50, 100, 200, 400 mg

Pain free, headache response, other efficacy outcomes such as nausea, photophobia, phonophobia

Dizziness, paresthesia, fatigue, nausea, vertigo and somnolence

Kuca B et al., 2018 [18]

USA; RCT

IHS 1.1 & 1.2.1

92/525; 42.4 ± 12.3

212/1027; 41.8 ± 11.9

5.1 ± 1.8

5.2 ± 2.1

100, 200 mg

Headache pain free, MBS free, other efficacy outcomes such as nausea, photophobia, phonophobia

Dizziness, paresthesia, fatigue, nausea, lethargy, and palpitations

Goadsby PJ et al., 2019 [19]

Multinational; RCT

IHS 1.1 & 1.2.1

100/545;

42.6 ± 12.9

309/1629; 42.7 ± 12.8

5.5 ± 2.4

5.2 ± 2.1

50, 100, 200 mg

Headac he pain free, MBS free, other efficacy outcomes such as nausea, photophobia, phonophobia

Dizziness, paresthesia, fatigue, nausea, lethargy and somnolence

  1. RCT Randomized controlled trial, IHS The International Headache Society criteria